Laboratory of Obesity and Aging Research, Genetics and Developmental Biology Center, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Trends Cell Biol. 2012 Oct;22(10):546-54. doi: 10.1016/j.tcb.2012.07.004. Epub 2012 Aug 10.
It is widely believed that calorie restriction (CR) can extend the lifespan of model organisms and protect against aging-related diseases. A potential CR mimetic is resveratrol, which may have beneficial effects against numerous diseases such as type 2 diabetes, cardiovascular diseases, and cancer in tissue culture and animal models. However, resveratrol in its current form is not ideal as therapy, because even at very high doses it has modest efficacy and many downstream effects. Identifying the cellular targets responsible for the effects of resveratrol and developing target-specific therapies will be helpful in increasing the efficacy of this drug without increasing its potential adverse effects. A recent discovery suggests that the metabolic effects of resveratrol may be mediated by inhibiting cAMP phosphodiesterases (PDEs), particularly PDE4. Here, we review the current literature on the metabolic and cardiovascular effects of resveratrol and attempt to shed light on the controversies surrounding its action.
人们普遍认为,热量限制(CR)可以延长模式生物的寿命并预防与衰老相关的疾病。白藜芦醇是一种潜在的 CR 模拟物,它可能对许多疾病具有有益的作用,例如 2 型糖尿病、心血管疾病和癌症,在组织培养和动物模型中也是如此。然而,目前形式的白藜芦醇作为治疗药物并不理想,因为即使在非常高的剂量下,它的疗效也很温和,而且有许多下游效应。确定白藜芦醇作用的细胞靶标,并开发针对这些靶标的治疗方法,将有助于在不增加其潜在副作用的情况下提高这种药物的疗效。最近的一项发现表明,白藜芦醇的代谢作用可能是通过抑制 cAMP 磷酸二酯酶(PDEs),特别是 PDE4 来介导的。在这里,我们回顾了白藜芦醇在代谢和心血管方面的作用的现有文献,并试图阐明围绕其作用的争议。